Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF
NCT01840735 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8
Last updated 2014-08-12
Summary
This study will determine the safety, tolerability, and pharmacokinetics of a single dose of GS-5737 administered with a 2.8% saline solution vehicle in adult subjects with CF.
Conditions
Interventions
- DRUG
-
GS-5737
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-05-31
- Primary Completion
- 2013-07-31
- Completion
- 2013-08-31
Countries
- United States
Study Locations
More Related Trials
-
Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.
NCT03589313 ·Status: COMPLETED ·Phase: PHASE1
-
GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis
NCT03474042 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease
NCT00357279 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation
NCT01746784 ·Status: COMPLETED ·Phase: PHASE1
-
A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers
NCT00999531 ·Status: COMPLETED ·Phase: PHASE1
-
Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation
NCT02275936 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis
NCT03375047 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
SD Cystic Fibrosis Study
NCT00605761 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
NCT06237335 ·Status: RECRUITING ·Phase: PHASE2
-
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis
NCT06429176 ·Status: RECRUITING ·Phase: PHASE2
-
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
NCT05504837 ·Status: RECRUITING ·Phase: PHASE1
-
Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)
NCT02707562 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis
NCT02566044 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Response to CFTR Modulators in CF Patients Under 18 Years
NCT04301856 ·Status: RECRUITING
-
Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
NCT00677365 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
NCT03056989 ·Status: COMPLETED ·Phase: PHASE1
-
Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis
NCT02718495 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
PK Study of N91115 in Cystic Fibrosis Patients
NCT02227888 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease
NCT00103714 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
NCT06526923 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
28 Day Repeat Dose in Cystic Fibrosis Patients
NCT00903201 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis
NCT00645788 ·Status: COMPLETED ·Phase: PHASE2
-
Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients
NCT00376428 ·Status: TERMINATED ·Phase: PHASE2
-
A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis
NCT01543191 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants
NCT03173573 ·Status: COMPLETED ·Phase: PHASE1